Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 14/20 | 0.54 |
| ▸ | BCL2 | P10415 | 11/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30622006 | 1.00 | BCL2L1 (0.54) | BCL2L1BCL2MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30112818 | 0.90 | BCL2 (0.46) | BCL2L1BCL2MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1955748 | 0.90 | BCL2L1 (0.59) | BCL2L1BCL2MCL1MAPTMAPK1 | |
| SCHEMBL14655243 | 0.89 | MAPT (0.59) | BCL2L1BCL2MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29855685 | 0.85 | BCL2L1 (0.58) | BCL2L1BCL2MCL1 | |
| SCHEMBL30019361 | 0.85 | BCL2L1 (0.54) | BCL2L1BCL2MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30112869 | 0.84 | BCL2L1 (0.58) | BCL2L1BCL2MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29588224 | 0.83 | BCL2L1 (0.53) | BCL2L1BCL2MCL1MAPTMAPK1 | |
| SCHEMBL30112781 | 0.83 | BCL2L1 (0.57) | BCL2L1BCL2MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29588272 | 0.83 | BCL2L1 (0.57) | BCL2L1BCL2MCL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116621860-A | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-111511748-B | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-111448198-B | Condensed heterocyclic derivatives as Bcl-2 inhibitors for the treatment of neonatal diseases | 广州麓鹏制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| CN-110483501-B | N- (phenylsulfonyl) benzamides and related compounds as BCL-2 inhibitors | 密歇根大学董事会 | 2022-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885BCL2 1/4885MCL1 16/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | BCL2L1 4/4885BCL2 3/4885MCL1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.